Trilogy Capital Inc. Sells 3,765 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Trilogy Capital Inc. lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,307 shares of the biopharmaceutical company's stock after selling 3,765 shares during the period. Trilogy Capital Inc.'s holdings in Gilead Sciences were worth $3,446,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in GILD. Algert Global LLC bought a new stake in Gilead Sciences during the second quarter worth approximately $254,000. AMF Tjanstepension AB lifted its holdings in Gilead Sciences by 14.7% in the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company's stock valued at $33,645,000 after acquiring an additional 51,390 shares during the last quarter. Czech National Bank boosted its position in shares of Gilead Sciences by 6.8% during the 3rd quarter. Czech National Bank now owns 253,618 shares of the biopharmaceutical company's stock valued at $21,263,000 after purchasing an additional 16,209 shares in the last quarter. Aprio Wealth Management LLC bought a new stake in shares of Gilead Sciences in the 3rd quarter worth approximately $290,000. Finally, Atomi Financial Group Inc. lifted its stake in Gilead Sciences by 36.0% during the third quarter. Atomi Financial Group Inc. now owns 6,081 shares of the biopharmaceutical company's stock valued at $510,000 after purchasing an additional 1,610 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the firm's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 142,180 shares of the company's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 572,824 shares of company stock valued at $53,611,715 in the last quarter. Corporate insiders own 0.16% of the company's stock.

Analyst Ratings Changes

Several research analysts have issued reports on GILD shares. The Goldman Sachs Group upped their price target on Gilead Sciences from $74.00 to $84.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. UBS Group boosted their price objective on Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a report on Thursday, November 21st. Leerink Partnrs upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday, October 21st. Finally, Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They issued an "outperform" rating and a $105.00 price target for the company. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the company's stock. According to MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and a consensus target price of $98.39.

Gilead Sciences Stock Performance

Shares of GILD traded down $2.00 during mid-day trading on Friday, hitting $96.04. The company's stock had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $100.51. The stock's 50-day moving average is $93.04 and its two-hundred day moving average is $86.76. The firm has a market capitalization of $119.69 billion, a PE ratio of 1,067.11, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the previous year, the firm posted $2.29 EPS. The business's revenue was up 7.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.